(Q37130262)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Future directions in regional treatment strategies for melanoma and sarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

M I Ross

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

D S Tyler

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

1 reference

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hyperthermia

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

301-309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Hyperthermic isolated limb perfusion for malignant melanoma: Response and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Thirty-five years of isolated limb perfusion for melanoma: indications and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Frequency and duration of remission after isolated limb perfusion for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Toxicity and morbidity of isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Modulation of resistance to regional chemotherapy in the extremity melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

In-transit melanoma: the role of alkylating-agent resistance in regional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

Natural history and selective management of in transit melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730701827573

10.1080/02656730701827573

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18393007%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference